[{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Amplitude Ventures"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Amplitude Ventures"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Palisade Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Palisade Bio","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Palisade Bio"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avenanthramide","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ceapro \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ceapro \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mescaline","moa":"5-HT2A receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the agreement, Palisade wil develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform, including GT-2108, an orally administered, gut-restricted, colon-specific PDE4 inhibitor prodrug in development for patients affect...

                          Product Name : GT-2108

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 09, 2023

                          Lead Product(s) : GT-2108

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Palisade Bio

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Avenanthramides provide relief from a host of skin conditions, such as eczema, allergic rash, chicken pox and insect bites. Ceapro is the only commercial manufacturer of commercially available avenanthramides extracted and purified from oats.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 22, 2022

                          Lead Product(s) : Avenanthramide

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : AUR200 is a recombinant Fc fusion protein designed to specifically BAFF and APRIL. BAFF and APRIL promote B cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions...

                          Product Name : AUR200

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 20, 2022

                          Lead Product(s) : AUR200

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : FSD Pharma holds exclusive worldwide (excluding Italy and Spain) licensing rights to FSD-201 for all conditions in all regulatory categories. FSD-201 (Palmitoylethanolamide) is a proprietary formulation of ultra-micronized palmitoylethanolamide (PEA).

                          Product Name : FSD201

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 31, 2022

                          Lead Product(s) : Palmitoylethanolamide

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : BMND06, (a novel formulation based on the psychedelic molecule mescaline), is naturally occurring psychedelic compound, binding and activating, the serotonin 5-HT2A receptor with high affinity, for treating a wide range of therapeutic indications.

                          Product Name : BMND06

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 24, 2022

                          Lead Product(s) : Mescaline

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b c...

                          Product Name : GT-2108

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 30, 2021

                          Lead Product(s) : GT-2108

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Amplitude Ventures

                          Deal Size : $1.2 million

                          Deal Type : Financing

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The Company has identified GT-2108 as a lead candidate for the treatment of inflammatory bowel diseases (IBD). GT-2108 is an orally-administered, colon-specific PDE4 inhibitor prodrug with potent anti-inflammatory properties.

                          Product Name : GT-2108

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 19, 2021

                          Lead Product(s) : GT-2108

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Amplitude Ventures

                          Deal Size : $11.0 million

                          Deal Type : Financing

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Revive is currently in the process of preparing its Investigational New Drug (“IND”) application for submission to the U.S. Food and Drug Administration (“FDA”) for CBD in the treatment of AIH.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          February 18, 2020

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank